Single-dose Ketamine for the Reduction of Pain and Depression in the Emergency Department
Status:
Withdrawn
Trial end date:
2020-02-05
Target enrollment:
Participant gender:
Summary
In this proposal, the investigators will determine if a single dose of intravenous (IV)
ketamine (in combination with midazolam) reduces pain severity, depressive symptoms and need
for opiate analgesics both in the ED and in the acute recovery period after ED discharge. The
investigators will compare the ketamine arm to an active placebo-controlled arm (with
midazolam).
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Maria Pacella
Collaborators:
University of Pittsburgh Physicians University of Pittsburgh Physicians (UPP)/UPMC Academic Foundation